#21. N-of-1: the Future of Personalized Drug Development

This episode of the podcast explores how Artificial Intelligence (AI) and N-of-1 trials are revolutionizing personalized drug development. Moving beyond population-based models, N-of-1 trials enable highly tailored therapies, especially for rare diseases. The discussion highlights AI’s role across the pipeline—from target discovery and molecule design to synthesis prediction and personalized treatment optimization. It also addresses challenges like data privacy, regulatory gaps, and scalability. Together, AI and N-of-1 approaches promise a future of faster, patient-specific drug development. Produced by Dr. Jake Chen.